Justin Zelin
Stock Analyst at BTIG
(1.89)
# 2,987
Out of 4,711 analysts
38
Total ratings
23.53%
Success rate
0.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Zelin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELVN Enliven Therapeutics | Initiates: Buy | $42 | $22.47 | +86.92% | 1 | Dec 13, 2024 | |
| CARM Carisma Therapeutics | Downgrades: Neutral | n/a | $0.42 | - | 2 | Dec 10, 2024 | |
| PSTX Poseida Therapeutics | Downgrades: Neutral | n/a | $9.45 | - | 2 | Nov 26, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $55 → $62 | $25.61 | +142.09% | 2 | Jul 9, 2024 | |
| JSPR Jasper Therapeutics | Initiates: Buy | $90 | $21.57 | +317.25% | 1 | Jul 8, 2024 | |
| TCRX TScan Therapeutics | Initiates: Buy | $12 | $2.97 | +304.04% | 1 | May 16, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Neutral | n/a | $0.18 | - | 2 | May 6, 2024 | |
| VKTX Viking Therapeutics | Maintains: Buy | $100 → $125 | $42.25 | +195.86% | 4 | Mar 26, 2024 | |
| VSTM Verastem | Assumes: Buy | $27 | $4.19 | +544.39% | 1 | Nov 21, 2023 | |
| MBIO Mustang Bio | Maintains: Buy | $20 → $16 | $0.17 | +9,435.16% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $91 | $28.33 | +221.27% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $0.91 | +998.90% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $1.51 | +959.60% | 1 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $37 | $7.94 | +365.99% | 2 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $35 | $13.08 | +167.58% | 1 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $34.08 | +164.08% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $9.01 | +244.06% | 1 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $16 | $85.00 | -81.76% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.50 | - | 3 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $10 | $2.65 | +277.36% | 3 | Nov 16, 2022 |
Enliven Therapeutics
Dec 13, 2024
Initiates: Buy
Price Target: $42
Current: $22.47
Upside: +86.92%
Carisma Therapeutics
Dec 10, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.42
Upside: -
Poseida Therapeutics
Nov 26, 2024
Downgrades: Neutral
Price Target: n/a
Current: $9.45
Upside: -
IDEAYA Biosciences
Jul 9, 2024
Maintains: Buy
Price Target: $55 → $62
Current: $25.61
Upside: +142.09%
Jasper Therapeutics
Jul 8, 2024
Initiates: Buy
Price Target: $90
Current: $21.57
Upside: +317.25%
TScan Therapeutics
May 16, 2024
Initiates: Buy
Price Target: $12
Current: $2.97
Upside: +304.04%
Lyra Therapeutics
May 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.18
Upside: -
Viking Therapeutics
Mar 26, 2024
Maintains: Buy
Price Target: $100 → $125
Current: $42.25
Upside: +195.86%
Verastem
Nov 21, 2023
Assumes: Buy
Price Target: $27
Current: $4.19
Upside: +544.39%
Mustang Bio
Aug 15, 2023
Maintains: Buy
Price Target: $20 → $16
Current: $0.17
Upside: +9,435.16%
Aug 11, 2023
Maintains: Buy
Price Target: $85 → $91
Current: $28.33
Upside: +221.27%
Aug 10, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $0.91
Upside: +998.90%
Jul 25, 2023
Initiates: Buy
Price Target: $16
Current: $1.51
Upside: +959.60%
Jul 3, 2023
Maintains: Buy
Price Target: $30 → $37
Current: $7.94
Upside: +365.99%
Jun 26, 2023
Maintains: Buy
Price Target: $34 → $35
Current: $13.08
Upside: +167.58%
Jun 13, 2023
Maintains: Buy
Price Target: $85 → $90
Current: $34.08
Upside: +164.08%
May 17, 2023
Initiates: Buy
Price Target: $31
Current: $9.01
Upside: +244.06%
Mar 28, 2023
Maintains: Buy
Price Target: $10 → $16
Current: $85.00
Upside: -81.76%
Dec 6, 2022
Downgrades: Neutral
Price Target: n/a
Current: $2.50
Upside: -
Nov 16, 2022
Maintains: Buy
Price Target: $21 → $10
Current: $2.65
Upside: +277.36%